Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 18,507 shares at $58.22 ($1.1M) on 2021-04-06, disclosed to the SEC on 2021-04-08.
Open-market sale of $1.1M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.22 | 1,889 | $110K | 10.1% |
| 2 | $58.22 | 1,889 | $110K | 10.1% |
| 3 | $58.22 | 1,233 | $72K | 6.6% |
| 4 | $58.22 | 1,233 | $72K | 6.6% |
| 5 | $59.10 | 3,685 | $218K | 20.0% |
| 6 | $59.10 | 2,402 |
| $142K |
| 13.0% |
| 7 | $59.10 | 3,685 | $218K | 20.0% |
| 8 | $59.10 | 2,402 | $142K | 13.0% |
| 9 | $59.95 | 54 | $3K | 0.3% |
| 10 | $59.95 | 35 | $2K | 0.2% |
| Total | $58.81 avg | 18,507 | $1.1M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |